Friday, April 1, 2011


Ind-Swift Laboratories Limited has received nod for two more DMFs filed in USA. The company has received DMF acceptance from USFDA for Temozolomide and Telmisartan.

Temozolomide is an anit-neoplastic drug with market size of US$700 mn and Temisartan is a Hypertension drug with market size of $1.6 bn.

The company has filed 20 DMFs with USFDA so far and received approval for all. The company is already commercially supplying 4 molecules to the US market.

The company recently received the PMDA, Japan approval for its manufacturing facilities. The company had already got approval for its facilities from the USFDA, MHRA, TGA, COS, KFDA and Who-GMP.

No comments:

Post a Comment